Tempus AI, Inc. (TEM)
TEM's Collab for Oncology Patient Population Is Gaining Attention
Tempus AI's partnerships with NYU Langone and Northwestern Medicine aim to expand genomic testing and data-driven cancer care.
Tempus AI, Inc. (TEM) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Tempus AI, Inc. (TEM) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Tempus AI Stock Rallies 105% in a Year: Should Investors Still Hold?
TEM has surged 105% in a year on AI-driven growth, FDA clearances and improving margins, but GAAP losses still cloud the outlook.
Tempus AI Stock Surges 82.4% in a Year: What's Driving It?
TEM shares are up 82.4% in a year as Genomics revenues surge, Data & Services scale, FDA clearances and EBITDA turns positive.
TEM's Stable Solvency and Financial Strength Are Gaining Attention
Tempus AI posts a strong Q3 2025 balance sheet with $760M cash, no current debt, and positive adjusted EBITDA, boosting flexibility and solvency.
How Tempus AI Is Building Scale While Near-Term Risks Persist
TEM is scaling via growing multi-quarter bookings, but delayed revenue conversion, MRD competition and rising losses keep near-term risks in focus.
TEM vs. HIMS: Which Medical Info Systems Stock Offers Greater Upside
Tempus AI and Hims & Hers are riding healthcare IT growth, but diagnostics scale and consumer demand set different upside paths.
How Tempus AI Is Advancing Toward Regulatory Pricing Catch-Up
TEM sees modest Q3 reimbursement gains, but FDA and ADLT pathways for xT, xF and xR assays could narrow its pricing gap over 2025-2026.
Tempus AI Approaching Profitability Despite GAAP Losses
TEM shows early profitability inflection with first positive Adjusted EBITDA in Q3 2025, raised revenue guidance and disciplined spending despite GAAP losses.
Tempus AI: A Healthcare Hyper-Growth Opportunity For The Risk Tolerant
Tempus AI (NASDAQ:TEM) is rated a strong buy for risk-tolerant investors, leveraging its vast proprietary healthcare data to drive precision medicine via AI and ML. TEM delivered 85% YoY revenue growth in Q3 2025, with organic oncology and hereditary testing volumes up 27% and 37%, and achieved positive adjusted EBITDA. The company's data moat, expanding test portfolio, and software ambitions position it for potential winner-take-all dominance in AI-driven diagnostics.
Tempus AI Turns Non-GAAP Profit on Surging Genomics and Data
Tempus AI posts first positive adjusted EBITDA as genomics testing accelerates and data bookings broaden. Zacks Rank #3 (Hold) with mixed Style Scores.
Tempus AI: Plenty Of Growth Catalysts Ahead, Grab It While It's Down
Tempus AI remains a Buy after a market-driven correction, with operational performance and partnerships strengthening the long-term thesis. TEM's organic revenue grew 28% y/y, gross margins improved 450bps to 63%, and liquidity increased to $760M, supporting continued investment and debt service. Management targets sustainable 25% annual genomics growth through 2028, with high-margin Data & Insights segment poised for outsized profitability.
